Boston Scientific Corp. (BSX) is geared up for its landmark MADIT-CRT trial final results, which will be announced on Sept 1. The MADIT trial is evaluating the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable cardioverter defibrillators (ICDs). MADIT-CRT is the world’s largest randomized NYHA Class I/II CRT-D trial engulfing more than 1,800 asymptomatic or mildly symptomatic patients across 110 centers in 14 countries.

Preliminary results from this trial were published on June 23, which indicated that the trial met its primary objectives. Results demonstrated a 29% reduction in death or heart failure in patients implanted with CRT-Ds as compared to ICDs.

Positive final results will boost demand for Boston’s cardiac resynchronization therapy defibrillators, which will essentially drive the company’s top-line. Boston Scientific reported fiscal second quarter results with the cardiac rhythm management segment registering revenue growth of 5% year over year. Within the CRM segment, ICD sales increased roughly 8% year over year to $454 million in the quarter.

Boston Scientific is a manufacturer of medical devices and products used in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio. The primary competitors include Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ). Based on the company’s performance, we have assigned a Neutral recommendation on the stock.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (MDT) Positive Drug Trial Results for MedtronicMedtronic, Inc. (MDT) announced positive results from its REVERSE trial, which was designed to evaluate...
2. (ATSI) ATS Medical Gets FDA ApprovalATS Medical, Inc. (ATSI) has received approval from the U.S. Food and Drug Administration (FDA)...
3. (MDT) Earnings Preview for MedtronicMedtronic, Inc. (MDT) will report its fiscal first quarter results tomorrow before the market opens....
4. (MDT) Medtronic Meets Earnings ExpectationsMedtronic, Inc. (MDT) reported results for the first quarter of fiscal 2010. Earnings per share...
5. (ABT) Abbott’s Stent Cleared for Immediate Launch in CanadaYesterday, Abbott Laboratories (ABT) received approval from Health Canada for its XIENCE V Everolimus Eluting...
6. (CSII) Cardiovascular Systems Better Than Expected ResultsCardiovascular Systems, Inc. (CSII) reported better-than-expected results for the fourth quarter of fiscal 2009. For...

Search Posts by Tag: Abbott Laboratories | ABT | Boston Scientific Corporation | BSX | JNJ | Johnson & Johnson | MDT | Medtronic Incorporated | St. Jude Medical Inc | STJ | Healthcare | Medical Instruments & Supplies

RSS Feeds by Tag: Abbott Laboratories | ABT | Boston Scientific Corporation | BSX | JNJ | Johnson & Johnson | MDT | Medtronic Incorporated | St. Jude Medical Inc | STJ | Healthcare | Medical Instruments & Supplies |

Other Posts by: vitalstocks | RSS Feed for this author